Literature DB >> 18572292

Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.

Laurent Camous1, Catherine Melander, Marion Vallet, Tarek Squalli, Bertrand Knebelmann, Laure-Hélène Noël, Fadi Fakhouri.   

Abstract

Lupus nephritis (LN) is a severe and frequent complication of systemic lupus erythematosus. For decades, cyclophosphamide-based regimens have been the gold standard in treating patients with LN. However, cyclophosphamide use is associated with increased morbidity and mortality, and thus alternative treatments are needed. We report 3 cases of severe class IV LN successfully treated with rituximab as an induction, as well as a long-term maintenance, treatment. Complete remission of LN, documented by means of a control kidney biopsy, occurred in all patients and was maintained during follow-up using rituximab as sole maintenance treatment. No severe infectious complications were observed during treatment with rituximab. Our data suggest that rituximab may prove to be an optimal maintenance treatment in patients with severe LN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572292     DOI: 10.1053/j.ajkd.2008.03.036

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

1.  Rituximab in childhood lupus myocarditis.

Authors:  Pooja Aggarwal; Surjit Singh; Deepti Suri; Amit Rawat; Nidhi Narula; Rohit ManojKumar
Journal:  Rheumatol Int       Date:  2011-04-06       Impact factor: 2.631

Review 2.  Rituximab in immunologic glomerular diseases.

Authors:  A Ahsan Ejaz; Abdo Asmar; Mourad M Alsabbagh; Nasimul Ahsan
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 3.  Diagnosis and treatment of lupus nephritis flares--an update.

Authors:  Ben Sprangers; Marianne Monahan; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

4.  Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.

Authors:  C Alejandro Arce-Salinas; Felipe Rodríguez-García; J Iván Gómez-Vargas
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

Review 5.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

6.  Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

Authors:  Catherine Melander; Marion Sallée; Pierre Trolliet; Sophie Candon; Xavier Belenfant; Eric Daugas; Phillipe Rémy; Virginie Zarrouk; Evangéline Pillebout; Christian Jacquot; Jean-Jacques Boffa; Alexandre Karras; Virginie Masse; Philippe Lesavre; Caroline Elie; Isabelle Brocheriou; Bertrand Knebelmann; Laure-Hélène Noël; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

7.  Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia.

Authors:  A Mardjuadi; M Soedirman; Buddy Utoyo; J J Rasker
Journal:  Clin Rheumatol       Date:  2008-12-13       Impact factor: 3.650

Review 8.  The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug.

Authors:  Juan M Mejía-Vilet; Isabelle Ayoub
Journal:  Front Med (Lausanne)       Date:  2021-02-16

9.  A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome.

Authors:  Jing Xu; Ying Ding; Li Wan; Qinghua Yang; Zhen Qu
Journal:  Int Urol Nephrol       Date:  2021-04-27       Impact factor: 2.370

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.